医学
脱发
乳腺癌
化疗
不利影响
入射(几何)
回顾性队列研究
头皮
内科学
癌症
临床终点
外科
单变量分析
皮肤病科
临床试验
多元分析
物理
光学
作者
Mangesh Mekha,Ashish Joshi,Vashishth Maniar,Udip Maheshwari,Kshitij Joshi,Pritam Kalaskar,Smit Sheth,Pradip Kendre,Dr Disha Morzaria,Reshma Korgavkar,Chandrashekhar Pethe,Sonal Dhande
标识
DOI:10.4103/ijd.ijd_345_23
摘要
Abstract Aim: Chemotherapy-induced alopecia (CIA) is the most common side effect of systemic treatment in breast cancer patients. Scalp cooling gained worldwide acceptance in preventing or mitigating CIA in patients undergoing chemotherapy. The objective of this study was to evaluate the efficacy and safety of the Paxman scalp cooling system (PSCS) in Indian breast cancer patients. Materials and Methods: This is a multi-centre, retrospective-observational study including patients registered from 1 st March, 2019 to 30 th April, 2021 undergoing chemotherapy for breast cancer by using PSCS. The primary end-point was the incidence of CIA after completing cycles of chemotherapy. Results: A total of 91 female patients were enrolled in the study, with a median age of 53 years (IQR: 44–62 years). The prevention of alopecia (grade 0 and grade I) was seen in 81%, while more than 50% hair loss (grade 2) was seen in 16.48% after completion of treatment. The univariate analysis results showed that CIA was significantly higher in patients who received anthracyclines (OR: 2.69; 95% CI: 1.04–6.958; P = 0.041) and in patients with a post-infusion cooling time of >150 minutes (OR: 8.409; 95% CI: 2.295–30.787; P = 0.001). The incidence of grade 2 (>50% hair loss) alopecia was 81.3% in patients <6 weeks and was 18.8% at >6 weeks of start of chemotherapy ( P < 0.0001). No adverse events were reported in 71.4% of patients, and the most common adverse event was headache (18.7%). Conclusion: PSCS is an effective and well-tolerated treatment modality for preventing CIA among breast cancer patients undergoing chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI